First-in-Class monoclonal antibody
PBP1710 specifically binds to CTHRC1 and exerts anti-metastasis and anti-tumor growth effects

Mechanism of Action

CTHRC1 promotes cancer cell migration through activation of the Wnt5 signaling pathway by forming CTHRC1-Wnt5-Fzd2/Ror2 complexes on cancer cells.

CTHRC1 stimulates formation of blood vessels (angiogenesis) in tumor tissues by upregulating the secretion of Ang-2, a Tie2 ligand, from endothelial cells. Activation of Ang-2/Tie2 axis in monocytes is critical in tumor angiogenesis.



[1] Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers. Cancer Cell Int (2021).

[2] CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9. BMC Cancer (2018).

[3] CTHRC1 promotes angiogenesis by recruiting Tie2-expressing monocytes to pancreatic tumors. Exp Mol Med (2016).

[4] CTHRC-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis (2013).

Phase of Clinical Research

Pipeline : PBP1710 (Anti-CTHRC1)

Category : mAb (monoclonal antibody)

Indication : Solid Tumors

Development Stage

  • Preparing for preclinical trial 25% 25%